Artios Pharma
128 employees on LinkedIn · 9 known investors
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Founders & leadership
R
Roy
Investors · 9
Andera PartnersParis
M VenturesLos Angeles · $10.8M
Novartis Venture FundBasel · $5M – $25M
Pfizer Venture Investments$5M – $20M
RA CapitalBoston
Sofinnova PartnersParis · $540K – $27M
SV Health InvestorsBoston · $1M – $20M
EQT Life SciencesreportedLuxembourg · $11M – $66M
Janus Henderson InvestorsreportedLondon
Funding
SEC filings, press & company announcements$115M disclosed across 1 of 2 rounds · 2025
- $115Mseries DNov 2025 · 2 sources
RA Capital Management (lead), SV Health Investors (lead), EQT Life Sciences, Janus Henderson Investors, Novartis Venture Fund, Sofinnova Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Artios Pharma do?
- Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
- Who are Artios Pharma's investors?
- Artios Pharma's investors include Andera Partners, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, RA Capital, Sofinnova Partners, SV Health Investors, EQT Life Sciences and 1 more.
- How much funding has Artios Pharma raised?
- Artios Pharma has disclosed $115M raised across 1 of its 2 known rounds.